Pfizer Inc. (PFE) Wins Ruling To Block Generic Lyrica Until 2018
2/7/2014 8:11:27 AM
Pfizer Inc., the world’s biggest drugmaker, won a court ruling that will block generic versions of its No. 1 product, Lyrica, in the U.S. until December 2018. Teva Pharmaceutical Industries Ltd. (TEVA), Actavis Plc (ACT) and Lupin Ltd. (LPC) are among the generic-drug makers that would infringe a valid patent on the pain medicine, the U.S. Court of Appeals for the Federal Circuit in Washington said in an opinion today on its website. The other generic-drug makers in the case were Sun Pharmaceutical Industries Ltd., Wockhardt Ltd. and Mylan Inc.
Help employers find you! Check out all the jobs and post your resume.
comments powered by